Biogen skyrockets after Alzheimer’s drug approval – time to buy?
- Biogen shares spiked 38.40% on Monday after the FDA approved its Alzheimer’s drug, aducanumab.
- BIIB stock pulled back more than 5% on Tuesday to trim Monday’s gains.
- Some analysts remain skeptical about the efficacy rate of the drug. So, is it time to buy BIIB stock?
Biogen Inc. (NASDAQ:BIIB) shares pulled back on Tuesday to trim Monday’s gains. The biotechnology stock rallied more than 38% after the FDA approved its Alzheimer’s drug, aducanumab. It is the first Alzheimer’s drug cleared by the Food and Drug Administration in almost 20 years.
Some analysts are skeptical of aducanumab’s efficacy rate in slowing down cognitive decline in people living with Alzheimer’s disease.
Is Biogen stock overvalued?
Are you looking for fast-news, hot-tips and market analysis? Sign-up for the Invezz newsletter, today.
Biogen shares have pulled back nearly 4% since Monday’s spike. However, at the current price of about $376.00 per share, the stock trades at a price-earnings ratio of $19.97. Under normal circumstances, this would be compelling to investors. However, just a few days ago, investors were only willing to pay about $286.00 per share for BIIB stock.
Investors did not think that Biogen shares were worth a higher premium before the aducanumab approval. The current P/E ratio factors the FDA’s approval of the new Alzheimers drug. But the problem is not everyone is convinced.
CFRA Research analyst Kevin Huang told CNBC’s Squawk Box that he remains skeptical of the drug’s efficacy rate. Huang said that he would have to observe how aducanumab performs in the next few years to change his mind. He has a price target of $363.00 on BIIB shares.
Technically, BIIB stock appears to have pulled back significantly after Monday’s spike. The pullback creates another opportunity for a rebound. However, the stock price has spiked in the past only to end up plunging back to previous lows. The same could happen again.
Investors will target short-term profits at around $420.06 or higher at $468.36. The key support levels are $322.13 and $267.46.
Bottom line: It may be worth waiting for BIIB stock price to drop before buying
Biogen shares have rallied to record highs after Monday’s aducanumab approval. The rally could entice investors to buy the stock.
However, as demonstrated over the last 18 months, these spikes are not new to BIIB stock. They always ended with a massive pullback. The same could happen again, which would open a better opportunity to buy the stock.
Where to buy right now
To invest simply and easily, users need a low-fee broker with a track record of reliability. The following brokers are highly rated, recognised worldwide, and safe to use: